Neumora Therapeutics’ (NMRA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock.

Several other equities research analysts have also weighed in on NMRA. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. Royal Bank of Canada lowered Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $29.00 to $4.00 in a research report on Thursday, January 2nd. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Bank of America dropped their price target on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Finally, William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Neumora Therapeutics Trading Up 3.0 %

Shares of NMRA stock opened at $1.74 on Friday. Neumora Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $21.00. The business’s 50 day moving average price is $5.34 and its 200-day moving average price is $9.78.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the previous year, the company posted ($1.14) earnings per share. On average, equities research analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in Neumora Therapeutics by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock valued at $851,000 after buying an additional 1,629 shares during the last quarter. SkyOak Wealth LLC raised its stake in shares of Neumora Therapeutics by 33.3% in the fourth quarter. SkyOak Wealth LLC now owns 20,000 shares of the company’s stock worth $212,000 after purchasing an additional 5,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Neumora Therapeutics in the fourth quarter worth $61,000. Charles Schwab Investment Management Inc. raised its stake in shares of Neumora Therapeutics by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company’s stock worth $7,464,000 after purchasing an additional 5,899 shares during the last quarter. Finally, PNC Financial Services Group Inc. purchased a new position in shares of Neumora Therapeutics in the fourth quarter worth $64,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.